[Source – medschool.duke.edu]
Psychedelics have long been used in indigenous cultures for their ability to alter mood and perception. Recent scientific interest in psychedelics has surged due to their potential therapeutic effects, particularly in treating psychiatric conditions such as anxiety and depression. However, the exact mechanisms by which psychedelics impact mood and behavior have remained elusive—until now.
A groundbreaking study led by Professor Vidita Vaidya from the Tata Institute of Fundamental Research (TIFR) in Mumbai, in collaboration with researchers from Cornell, Columbia, and Yale Universities, has provided new insights into how psychedelics may alleviate anxiety without inducing hallucinations.
Identifying the Brain Region Responsible
In the study, the psychedelic drug DOI was administered to rats and mice. Behavioral tests, such as the elevated plus maze and open field test, revealed that DOI significantly reduced anxiety-related behaviors. To pinpoint the exact part of the brain responsible for this effect, the researchers infused DOI directly into targeted brain regions, discovering that the ventral hippocampus plays a critical role in reducing anxiety.
Interestingly, the study found that while the ventral hippocampus is essential in decreasing anxiety, it is not responsible for producing the hallucinatory effects often associated with psychedelics. This suggests that different brain regions are responsible for different behavioral changes triggered by psychedelics.
Role of Serotonin Receptors in Anxiety Reduction
The researchers further uncovered that the serotonin2A receptor in the ventral hippocampus is key to the anti-anxiety effects of DOI. The serotonin2A receptor has long been associated with mood regulation, but its precise role in anxiety behavior had not been clearly defined until this study. Importantly, the team was able to rule out contributions from other brain regions, such as the prefrontal cortex and amygdala, which are typically linked to emotion regulation.
How DOI Affects Neurons to Reduce Anxiety
Electrophysiological studies revealed that the psychedelic DOI increases the activity of a specific type of neuron known as parvalbumin-positive, fast-spiking interneurons in the ventral hippocampus. These neurons express the serotonin2A receptor, and their heightened activity seems to be the cellular trigger through which DOI reduces anxiety.
To test this hypothesis, the team used advanced chemogenetic techniques to activate this particular subclass of neurons in animal models, even in the absence of the drug. Remarkably, activating these neurons alone was sufficient to reduce anxiety behaviors, demonstrating their central role in anxiety regulation.
Genetic Evidence Supports Findings
To solidify their findings, the researchers employed a genetic knockout mouse model that lacked the serotonin2A receptor throughout the body. They then selectively restored the receptor on parvalbumin neurons in the ventral hippocampus. This restoration was enough to reproduce the anxiety-reducing effects of DOI, further confirming the critical role of these neurons in regulating anxiety.
Implications for Non-Hallucinatory Therapeutics
This study is the first to map out the precise brain region and neuronal population that psychedelics target to influence anxiety behavior. More importantly, it demonstrates that the brain circuits responsible for reducing anxiety do not contribute to hallucinations, opening up the possibility of developing psychedelic-inspired drugs that treat anxiety disorders without causing altered perceptions.
The findings could have major implications for the treatment of anxiety disorders, offering a new avenue for the development of drugs that harness the therapeutic potential of psychedelics while minimizing undesirable side effects such as hallucinations. This research marks a significant step forward in understanding the neurobiological underpinnings of psychedelic therapy and its application in mental health treatment.
A New Horizon for Anxiety Treatments
With this breakthrough, scientists are closer to unlocking the full potential of psychedelics in treating anxiety disorders. As psychedelic research continues to evolve, these findings could pave the way for safer, more effective treatments that provide relief for anxiety without the need for hallucinatory experiences.
The study not only deepens our understanding of how psychedelics impact the brain but also opens the door for new therapeutic possibilities that could benefit millions of people worldwide struggling with anxiety.
Did you find this news helpful? Visit more of our blogs! Healthcare 360 Magazine
